1 VD during the first 6 months of GnRH agonist
therapy of 1.91 (95% CI, 1.66 to 2.20), an HR of CVD wit
2 uclear cells, and duration of antiretroviral
therapy of 13 years.
3 to better treat BPH patients who failed the
therapy of 5alpha-reductase inhibitors.
4 Combination direct-acting antiviral
therapy of 8-24 weeks is highly effective for the treatm
5 as a promising strategy for allele-specific
therapy of ABCC6-associated calcification disorders.
6 udies, POEM may become one of the first-line
therapies of achalasia in the next future.
7 sue plasminogen activator, the only approved
therapy of acute ischemic stroke still remains unknown.
8 nts is an established component of induction
therapy of acute lymphoblastic leukemia.
9 orbidities on 1-year mortality after initial
therapy of acute myeloid leukemia (AML) and (2) a novel,
10 Effective
therapy of acute myeloid leukemia (AML) remains an unmet
11 ffering new therapeutic opportunities in the
therapy of AD and other neurodegenerative diseases assoc
12 role for resveratrol in the prophylaxis and
therapy of AD.
13 a provide a rationale to explore combination
therapy of adoptive HSPC-NK cells and DAC in patients wi
14 hemoradiation, as a basis for individualized
therapy of advanced esophageal cancer.
15 For
therapy of advanced MTC, the Food and Drug Administratio
16 biomarkers, functional imaging, and systemic
therapy of advanced NETs and discuss results of recent p
17 ith carboplatin and paclitaxel as first-line
therapy of advanced nonsquamous NSCLC.
18 performance and mechanism of the combination
therapy of aFGF-nanoparticles (aFGF-NP) and ultrasound-t
19 yntenin (SDCBP) provides a direct target for
therapy of aggressive cancers such as GBM, and defined s
20 r targeted biopsy and localization for focal
therapy of aggressive prostate tumors as well as assessm
21 ur findings have clear implications for gene
therapy of airway disorders where plasmid DNA transfecti
22 immune cells was dispensable for successful
therapy of allergic airway inflammation (AAI) with dexam
23 rgenicity would allow improved diagnosis and
therapy of allergies and would provide insights for safe
24 y control and to assist in the diagnosis and
therapy of allergy symptoms.
25 DYRK1A has emerged as a potential target for
therapies of Alzheimer's disease using small molecules.
26 FRbeta is a promising target for CAR T-cell
therapy of AML, which may be augmented by combination wi
27 lidating CD33 as a target for antibody-based
therapy of AML.
28 l target pairings hold great promise for CAR
therapy of AML.
29 For these patients, initiating statin
therapy of an appropriate intensity to reduce ASCVD risk
30 trichomoniasis can be cured with single-dose
therapy of an appropriate nitroimidazole antibiotic, but
31 r therapy in mice, tumor PS and photothermal
therapy of anti-CD11b Abs-linked gold nanorods (GNRs-CD1
32 e disparities in access to renal replacement
therapy of any kind and in the use of transplantation or
33 NJ5MUT could allow noninvasive diagnosis and
therapy of APAs carrying KCNJ5 mutations.
34 d tumor growth kinetics, whereas combination
therapy of aspirin and a PI3K inhibitor further attenuat
35 of the current standard of dual antiplatelet
therapy of aspirin with clopidogrel versus aspirin plus
36 , opening prospects for diagnosis and causal
therapy of asthma.
37 Current approaches to the diagnosis and
therapy of atherosclerosis cannot target lesion-determin
38 er ambulatory surgeries and as a maintenance
therapy of atopic dermatitis (AD).
39 have a therapeutic potential for Treg-based
therapies of autoimmune disorders.
40 Our findings may have implications for the
therapy of autoimmune conditions, such as inflammatory b
41 ntial as a novel anti-inflammatory agent for
therapy of autoimmune diseases such as MS.
42 idants represent an alternative approach for
therapy of autoimmune disorders; however, dietary antiox
43 A combined
therapy of avasimibe plus an anti-PD-1 antibody showed b
44 nery has become an established target in the
therapy of B-cell malignancies.
45 cation of GRP-R radioligands for imaging and
therapy of BC by introducing valid preclinical in vitro
46 ntial DNA target for genome-editing-mediated
therapy of beta-hemoglobinopathies.
47 nosis of bony disease and (223)RaCl2 for the
therapy of bone metastases-were recently shown to be sup
48 tifies close follow-up and early, aggressive
therapy of both AT and AF.
49 hesis, and its enhancement has potential for
therapy of both primary and secondary causes of hyperamm
50 unmet need for well-tolerated and effective
therapy of BPSD.
51 on of ER-alpha with CaM may be useful in the
therapy of breast carcinoma.
52 ise as new tools for research, diagnosis and
therapy of C. difficile associated disease.
53 delivery vehicles can facilitate multimodal
therapies of cancer by promoting tumour-selective drug r
54 dichotomous immune responses relevant to the
therapy of cancer and autoimmunity.
55 as ideal miniature reactors for photodynamic
therapy of cancer cells.
56 act in conjunction with chemo- or radiation
therapy of cancer cells.
57 non-viral or viral vectors for suicide gene
therapy of cancer make more informed decisions when choo
58 portant role for the CD28/B7 pathway in PD-1
therapy of cancer patients.
59 Therapy of cancer with radiolabeled monoclonal antibodie
60 s noninvasive image-guided conformal thermal
therapy of cancer.
61 een used for stem cell mediated suicide gene
therapy of cancer.
62 n 806 patients receiving adjuvant first-line
therapy of carboplatin and paclitaxel with curative inte
63 e the symptomatic and potentially lifesaving
therapies of cardiac pacemakers while mitigating many of
64 MiPs should be further explored for combined
therapy of cardiac and skeletal muscles.
65 Early detection and prompt
therapy of cardiotoxicity appear crucial for substantial
66 al correlates, and response to heart failure
therapy of cardiotoxicity.
67 peutic modulation of HIF hydroxylases in the
therapy of cardiovascular disease.
68 Ca(2+) antagonist drugs are widely used in
therapy of cardiovascular disorders.
69 Combination
therapy of ceftriaxone and lansoprazole is associated wi
70 12D, an important genetic marker for guiding
therapy of certain cancers.
71 The
therapy of certain diseases, such as acute myeloid leuke
72 ABP5 may constitute a new class of drugs for
therapy of certain types of cancer.
73 ying A1 as a possible therapeutic target for
therapy of certain types of mast cell-driven allergy sym
74 port the potential utility of (R)-BPO-27 for
therapy of CFTR-mediated secretory diarrheas.
75 etronidazole, vancomycin and fidaxomicin are
therapies of choice for Clostridium difficile infection.
76 rcome before LVADs will be considered as the
therapy of choice for all patients with advanced heart f
77 stem cell transplantation (HSCT) remains the
therapy of choice for most patients with JMML, curing mo
78 the anatomic area of the slow pathway is the
therapy of choice for symptomatic AVNRT, regardless of w
79 vealed potential targets for pharmacological
therapies of cholestatic liver diseases.
80 tic transporters and are natural targets for
therapy of cholestatic liver diseases.
81 lead to novel approaches for prevention and
therapy of cholesterol-driven neurodegenerative disease.
82 pproaches, as highlighted by the case of the
therapy of chronic hepatitis C.
83 cells may be highly suitable for cell-based
therapy of chronic hepatocyte-depleting disorders.
84 Adoptive cell
therapy of chronic lymphocytic leukemia (CLL) with chime
85 to be associated with resistance to targeted
therapy of chronic lymphocytic leukemia (CLL) with the B
86 y approved with chlorambucil for the initial
therapy of chronic lymphocytic leukemia (CLL).
87 Clinically, combined
therapy of cisplatin (CDDP) and metformin is an effectiv
88 therapies will further refine the frontline
therapy of CLL.
89 /T-bet/CD38 pathway could play a role in the
therapy of CLL.
90 open up new perspectives for efficient gene
therapy of cochlear and vestibular disorders by showing
91 te detection, delineation and rapid targeted
therapy of colon cancer or precancerous lesions.
92 The
therapy of complex neurodegenerative diseases requires t
93 didacy of CNGA3 ACHM for clinical trials for
therapy of cone photoreceptors.
94 n for the epidemiological association of ICS
therapy of COPD patients with increased risk for CAP, an
95 that are promising targets for regenerative
therapies of corneal injuries.
96 R monoclonal antibody therapies for targeted
therapy of CRC.
97 chniques with respect to early diagnosis and
therapy of CS will have to be determined in future studi
98 n was not required) and for whom no suitable
therapy of curative intent or higher priority existed fr
99 rosclerosis indicate a novel approach toward
therapy of CVD.
100 vide a mechanistic rationale for combination
therapy of CXCR4 and BCL-2 inhibitors to treat a common
101 y applying these principles to a combination
therapy of daclatasvir and asunaprevir.
102 Recent clinical studies on combination
therapy of decitabine (DAC) and arsenic trioxide (ATO) h
103 which has great implication in photodynamic
therapy of deep-tissue cancers.
104 Combination
therapy of diabetic RIP-LCMV and NOD mice with anti-CD3
105 CFTR inhibitor (R)-BPO-27 for antisecretory
therapy of diarrheas caused by bacterial enterotoxins.
106 is and even the possibility for simultaneous
therapy of diseases caused by bacterial infections.
107 Immediate diagnosis and appropriate
therapy of dissecting aneurysms is necessary for good cl
108 In adoptive
therapy of disseminated leukemia, CD200R-CD28-transduced
109 onment could serve as a ray of light for the
therapy of drug-resistant infections.
110 i-inflammatory approaches to prophylaxis and
therapy of DVT.
111 hort-term safety profile for the combination
therapy of E10030 and ranibizumab.
112 and, as such, may be considered for empiric
therapy of endophthalmitis caused by yeast or mold.
113 ion after 1 year of follow-up, a combination
therapy of endovascular revascularization followed by su
114 Combination
therapy of endovascular revascularization plus supervise
115 n important consideration for prevention and
therapy of enteric disease.
116 ed Tasmanian devils, and regression followed
therapy of experimentally induced DFTD tumours in three
117 rected HSPCs, opening new prospects for gene
therapy of FA patients.
118 ese data provide a rationale for combination
therapy of Fc-engineered antibodies such as BI 836858 wi
119 a limited but relevant role in the adjuvant
therapy of gastric cancer (GC) patients.
120 vide information for assessing diagnosis and
therapy of genetic disorders linked to the deregulation
121 n in antibiotic-treated mice, and antibiotic
therapy of germ-free mice caused no additional abnormali
122 Antivascular alpha-particle
therapy of glioblastoma in the transgenic Ntva model res
123 ood-brain barrier (BBB) after antiangiogenic
therapy of gliomas with bevacizumab may result in a decr
124 seltamivir, shows promise for prophylaxis or
therapy of group I and II IAVs with pandemic potential.
125 d favorable pharmacokinetics for imaging and
therapy of GRPR-expressing tumors.
126 ectable viral load 12 weeks after completing
therapy) of &
gt;90% in most patients.
127 tion of NFAT opens an avenue for an advanced
therapy of GvHD maintaining protective GvL.
128 may be a rational target for anti-angiogenic
therapy of HCC.
129 led a new pathway for the molecular targeted
therapy of HD.
130 MMP-responsive SELPs for viral mediated gene
therapy of head and neck cancer.
131 for genetic modification of the enhancer for
therapy of hemoglobin disorders.
132 IFNalpha-based antiviral
therapy of hepatitis delta was independently associated
133 Importance: Current
therapy of herpes infections relies on nucleoside analog
134 Differential diagnosis and
therapy of heterogeneous breast tumors poses a major cli
135 Targeted
therapy of HGF in combination with gemcitabine in a prec
136 f a clinically relevant subtype for tailored
therapy of HGSC.
137 ed AC133-positive GBM-SCs in models of local
therapy of highly invasive GBM.
138 ether there is any role for definitive local
therapy of his primary bladder tumor with radical cystec
139 Despite the recent advances in the
therapy of HIV-associated and aggressive lymphomas, pati
140 le, to improve mechanistic understanding and
therapy of human cardiac fibrillation.
141 rug target for inducing immunosuppression in
therapy of human disease as well as a rapidly emerging d
142 onal research as they may allow modeling and
therapy of human diseases in vivo.
143 ic nervous system in the pathophysiology and
therapy of human hypertension.
144 tal mouse model for studying the biology and
therapy of human marginal-zone B-cell lymphomas.
145 Recently, the neuroprotective
therapy of hypothermia has emerged as the standard of ca
146 tericin B (AmB) deoxycholate for the primary
therapy of IA.
147 Here, we developed a combinatorial gene
therapy of IAPP and LEP, where two genes are inserted in
148 otherapy or PTT, the combinational chemo-PTT
therapy of ICG-EPI NPs with NIR laser irradiation synerg
149 Recently, a combination
therapy of imiquimod and GV has shown an inhibitory effe
150 to design new immunomodulatory drugs in the
therapy of immune-related diseases.
151 FQN resistance would also be lower with FQN
therapy of infected contacts.
152 t of improved strategies for CPE control and
therapy of infections.
153 rs have strong potential applications in the
therapy of inflammation and, likely, of autoimmune disea
154 serious infections due to available medical
therapies of inflammatory bowel disease (IBD) remains co
155 ng drugs should be further evaluated for the
therapy of inflammatory and autoimmune disorders.
156 Thus, IRAK1 is a promising novel target for
therapy of inflammatory bowel diseases.
157 erspectives for an effective pharmacological
therapy of intracranial vascular cavernomas.
158 Aspergillus DNA for the early diagnosis and
therapy of invasive aspergillosis (IA) in high-risk hema
159 rial that studied primary as well as salvage
therapy of invasive mucormycosis showed efficacy with is
160 ion when compared with standard single-agent
therapy of investigator's choice in Checkmate 141; here
161 -of-life outcomes compared with single-agent
therapy of investigator's choice in patients with platin
162 ading of leukocytes may hold promise for the
therapy of IPA.
163 ls (ECFCs) are promising candidates for cell
therapy of ischemic diseases, as less than 10% of patien
164 Combination
therapy of ISF35 with systemic anti-PD-1 generates great
165 The combinatorial peptidergic
therapy of islet amyloid polypeptide (IAPP) and leptin (
166 with inhibitory synthetic molecules for the
therapy of KRAS-dependent tumors is feasible.
167 consistent effect on the median duration of
therapy of laBCC and mBCC.
168 Fluoroquinolone (FQN)
therapy of latent tuberculosis infection among contacts
169 nd NK cells might play a crucial role in the
therapy of leukemia.
170 receptor might be a potential target for the
therapy of Leydig cell tumors.
171 e last workforce study in the prevalence and
therapy of liver diseases and training may impact workfo
172 Despite overall progress in the
therapy of local and locally advanced esophageal, gastro
173 rd ATRA and chemotherapy (CHT) in first-line
therapy of low- or intermediate-risk acute promyelocytic
174 Here we show that a combination
therapy of low-dose anti-CD3 with a clinical-grade self-
175 A reduction in dFLC after
therapy of &
lt;10 mg/L was associated with a better OS and
176 D8 T cells proliferating in blood after PD-1
therapy of lung cancer patients were predominantly CD28-
177 ovide a promising strategy for NQO1-targeted
therapy of lung cancer with improved safety and antitumo
178 ant HBoV1 vectors, a promising tool for gene
therapy of lung diseases.
179 ontributes information for the diagnosis and
therapy of LV thrombus after STEMI.
180 per group were treated with (a) combination
therapy of magnetic resonance imaging heating guidewire-
181 ications is exemplified here as photodynamic
therapy of malignancies.
182 Dantrolene is the first line
therapy of malignant hyperthermia.
183 advances have been made in the diagnosis and
therapy of malignant small round cell tumors that affect
184 reatment but will also be beneficial for the
therapy of many other solid tumors.
185 77)Lu-PSMA-617 is a promising new option for
therapy of mCRPC and deserves more attention in larger p
186 et and prognostic biomarker for the improved
therapy of medulloblastoma.
187 Therapy of melanoma patients harboring activating mutati
188 31)I]radiolabeled compounds for radionuclide
therapy of melanoma.
189 pecific defects, paves the way for precision
therapy of metabolic diseases.
190 SMA) is an excellent target for radionuclide
therapy of metastasized castration-resistant prostate ca
191 ane antigen (PSMA) are under development for
therapy of metastasized prostate cancer.
192 rly effective: first is in the diagnosis and
therapy of metastatic bone cancer, in which radioactive
193 posomal doxorubicin (CREKA-Lipo-Dox) for the
therapy of metastatic breast tumor.
194 ns the prospect of NIS-mediated radionuclide
therapy of metastatic cancer after MSC-mediated gene del
195 , due to their significance in prognosis and
therapy of metastatic cancer.
196 by (124)I PET/CT-based dosimetry for (131)I
therapy of metastatic DTC when the same patient was prep
197 s THW patient preparation methods for (131)I
therapy of metastatic DTC.
198 Experimental
therapy of mice bearing peritoneal MKN-45P xenografts an
199 sistent evidence pertaining to the impact of
therapy of mild OSA on neurocognition, mood, vehicle acc
200 sults show that genotoxic agents used in the
therapy of MM (i.e., doxorubicin and melphalan) selectiv
201 ammatory cells, indicating a potential novel
therapy of MSC-Exo for uveitis.
202 s with vancomycin for empiric and definitive
therapy of MSSA bloodstream infections among patients ad
203 proach for making antigen-specific Tregs for
therapy of multiple diseases.
204 adaptor as a potential novel target for the
therapy of multiple sclerosis.
205 on and animal survival for in vivo stem cell
therapy of myocardial infarction.
206 A new powerful tool for investigations and
therapies of myosin-based cardiomyopathies is now within
207 cids (BA) are linked to the pathogenesis and
therapy of NASH.
208 or the defense of certain infections and for
therapy of neoplastic diseases.
209 o sheds new light on cost-effective and safe
therapy of neurodegenerative diseases.
210 intigraphy and peptide receptor radionuclide
therapy of neuroendocrine tumors and provide successful
211 availability and use of DOTA analogs in the
therapy of neuroendocrine tumors, we expect that (68)Ga-
212 intigraphy and peptide receptor radionuclide
therapy of neuroendocrine tumors.
213 c gene editing has significant potential for
therapy of neuromuscular disorders.
214 pyrrolo[2,3-d]pyrimidine antifolate used for
therapy of nonsquamous nonsmall cell lung cancer (NS-NSC
215 gnaling, viability, and response to targeted
therapies of oncogene-addicted cells.
216 CT guided RA
therapy of OO is minimally invasive, effective and secur
217 potential for repurposing probiotics for the
therapy of osteoporosis.
218 can also contribute to the understanding and
therapy of other IDDs.
219 P) chemotherapy is a promising post-surgical
therapy of ovarian cancer, but the full potential is yet
220 MAS in childhood may inform study design for
therapy of PALF.
221 sonian agents, which are much needed for the
therapy of Parkinson's disease.
222 molecule with potential implications for the
therapy of pathologic neovessel formation in the retina
223 nitor cells (hBTSCs) are being used for cell
therapies of patients with liver cirrhosis.
224 udy aimed to assess whether NT-proBNP-guided
therapy of patients with acute decompensated HF using a
225 ng via MET and CD44 during anti-EGF receptor
therapy of patients with colorectal cancer or in patient
226 taneous revascularization revolutionized the
therapy of patients with coronary artery disease.
227 f (68)Ga-PSMA-11 PET for planning (223)RaCl2
therapy of patients with metastatic prostate cancer and
228 relevance for the diagnosis, prognosis, and
therapy of patients.
229 Nanobody (JVZ-007) for targeted imaging and
therapy of PCa.
230 MA-617, therefore enables both diagnosis and
therapy of PCa.
231 ature-based subtyping may guide personalized
therapy of PDAC in the context of biomarker-driven prosp
232 valuable treatment option in the neoadjuvant
therapy of PDAC.
233 ongoing management, and empirical antifungal
therapy of pediatric FN were reviewed; the most substant
234 that miR-96 might be a potential target for
therapy of pediatric SE.
235 sufficiency, it may be a valuable target for
therapy of poorly vascularized solid tumors.
236 atherothrombotic events, which makes aspirin
therapy of potential value in these subjects.
237 fludarabine cyclophosphamide (G-FC) for the
therapy of previously untreated fit patients with CLL.
238 Combined approach
therapy of PRF + 1% ALN for IBD treatment in patients wi
239 (PSMA), an attractive target for imaging and
therapy of prostate cancer, could serve as a suitable bi
240 on to existing ligands proposed for targeted
therapy of prostate cancer, RPS-027 has tumor-to-tissue
241 around the world as a target for imaging and
therapy of prostate cancer.
242 estigated extensively for both diagnosis and
therapy of prostate cancer.
243 as an excellent target for both imaging and
therapy of prostate cancer.
244 aimed to identify key principles of targeted
therapy of protein kinases and their application to the
245 testing for immunogenicity and how biologic
therapy of psoriasis may be tailored on the basis of imm
246 Treatment failure after
therapy of pulmonary tuberculosis (TB) infections is an
247 neuromodulating devices in the experimental
therapy of RA and possibly other autoimmune and autoinfl
248 fore represents an attractive target for the
therapy of RA.
249 The
therapy of relapsed chronic lymphocytic leukemia (CLL) h
250 The primary
therapy of renal cancer is the surgical removal.
251 suggested a potential role of statins in the
therapy of Rett syndrome.
252 f thrombotic development and of thrombolytic
therapy of rtPA observed from human ischemic stroke.
253 early diagnosis and the development of novel
therapies of schizophrenia.
254 sis may provide a strategy for prognosis and
therapy of second-generation TEVGs.
255 an direct research into the pathogenesis and
therapy of seemingly unrelated common diseases.
256 o neurodegeneration to be useful targets for
therapy of senile dementias.-Goetzl, E.
257 Emergence of daptomycin resistance during
therapy of serious enterococcal infections is a major cl
258 aling is considered a rational target in the
therapy of several cancers, particularly those harbourin
259 ase complex (IKK) has been implicated in the
therapy of several chronic inflammatory diseases includi
260 uld be a promising approach for photodynamic
therapy of skin tumors.
261 tion of SMN exon 7 inclusion for a potential
therapy of SMA.
262 ensively studied as a target for imaging and
therapy of solid malignancies and neuropathologies.
263 gen T-cell receptors (CAR) for adoptive cell
therapy of solid tumors.
264 apy are successfully applied for imaging and
therapy of somatostatin receptor-expressing neuroendocri
265 alapril 20 mg/day) were randomized to add-on
therapy of spironolactone 25 mg, hydrochlorothiazide (HC
266 might be a candidate for molecular targeted
therapies of SSc.
267 s remain about the role of DAPT in long-term
therapy of stable post-myocardial infarction (MI) patien
268 and its regulators as potential targets for
therapies of T cell-mediated autoimmunity.
269 Options for targeted
therapy of T-cell malignancies remain scarce.
270 ty of using CD7 CAR T cells for the targeted
therapy of T-cell malignancies.
271 models revealed that TACE and a combination
therapy of TACE and sorafenib were significant prognosti
272 This may represent a novel approach to
therapy of Th17-mediated diseases by elevating soluble I
273 may provide a source of cells for cell-based
therapies of the inner ear.
274 ty and efficacy of a single-dose triple-drug
therapy of the antifilarial drugs diethylcarbamazine (DE
275 nale for development of complement-targeting
therapy of the disease.
276 illustrates the substantial progress made in
therapy of the disease.
277 ing cell engraftment and thus improving cell
therapy of the infarcted myocardium.
278 Oral calcitriol, compared with placebo,
therapy of the patients with SR asthma significantly imp
279 ed the pregnancy to allow immediate systemic
therapy; of the remaining 36 women, 24 received antenata
280 There are no definite guidelines for
therapy of these aneurysms.
281 n-specific T cell responses are critical for
therapy of these diseases.
282 ation of irreversible EGFR inhibitors in the
therapy of these tumors.
283 medicine and in decision making for targeted
therapy of these tumors.
284 ion may be a potential strategy for clinical
therapy of this disorder.
285 erisation, understanding of pathogenesis and
therapy of this disorder.
286 could potentially be used for prevention and
therapy of this group of diseases.
287 We showed that after subchronic
therapy of three intravenous injections over 5weeks at 2
288 Radioiodide (RAI)
therapy of thyroid cancer exploits the relatively select
289 rofloxacin is the standard treatment in self-
therapy of traveler's diarrhea except when patients are
290 PNA is a promising molecule for antisense
therapy of trinucleotide repeat disorders.
291 icted T cells in the control, diagnosis, and
therapy of tuberculosis.
292 Anti-CD3
therapy of type 1 diabetes results in a temporary halt o
293 l programs assessing GPR119 agonists for the
therapy of type 2 diabetes.
294 Despite improvements in the
therapy of underlying heart disease, sudden cardiac deat
295 ent of radiation retinopathy and alternative
therapies of uveal melanoma.
296 of exosomes and their role in prognosis and
therapy of various diseases and the above results contri
297 ools for diagnostic imaging and radionuclide
therapy of various diseases.
298 ection of the lung is a step toward targeted
therapy of VZV-induced disease.
299 , rituximab is now the preferred second-line
therapy of warm antibody hemolytic anemia in adults, alt
300 who received direct oral factor Xa inhibitor
therapy, of whom 57 had vaginal bleeding events, includi